Effects of genetic defects in the CYP2C19 gene on the N‐demethylation of imipramine, and clinical outcome of imipramine therapy

The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients

1987 • 1,610 citations

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

1994 • 958 citations

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

1994 • 749 citations

Newer antidepressants and the cytochrome P450 system

1996 • 488 citations

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

1985 • 459 citations

The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

1992 • 456 citations

Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

1984 • 368 citations

Clinical Implications of Imipramine Plasma Levels for Depressive Illness

1977 • 322 citations

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1996 • 314 citations

Genetic polymorphism of S-mephenytoin hydroxylation

1989 • 292 citations

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

1989 • 221 citations

Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms

1993 • 214 citations

Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities

1989 • 178 citations

Imipramine: Clinical effects and pharmacokinetic variability

1977 • 176 citations

Slow Omeprazole Metabolizers Are Also Poor S-Mephenytoin Hydroxylators

1990 • 169 citations

Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.

1993 • 168 citations

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine

1991 • 139 citations

Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects*

1996 • 118 citations

Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers

1994 • 94 citations

The cardiac effects of therapeutic plasma concentrations of imipramine

1978 • 94 citations

Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms

1994 • 92 citations

The pharmacogenetics of the selective serotonin reuptake inhibitors

1993 • 90 citations

Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes

1992 • 89 citations

First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

1988 • 87 citations

Selective Serotonin Reuptake Inhibitors and Tricyclic Antidepressants in Combination

1995 • 50 citations

Steady-State Plasma Concentrations of Imipramine and Desipramine in Relation to S-Mephenytoin 4'-Hydroxylation Status in Japanese Depressive Patients

1996 • 43 citations

Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.

1994 • 41 citations

Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients.

1993 • 28 citations

Simultaneous High-Performance Liquid Chromatography-Electrochemical Detection Determination of Imipramine, Desipramine, Their 2-Hydroxylated Metabolites, and Imipramine N-Oxide in Human Plasma and Urine

1993 • 26 citations

Studies on Cytochrome P450 Responsible for Oxidative Metabolism of Imipramine in Human Liver Microsomes.

1993 • 23 citations

UKU Side Effects Rating Scale

1987 • 13 citations

Cited By (0)

No citing papers found in database